Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma

被引：0
|
作者：
Liu, Jiajian
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2663
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors
    Liu, Jiajian
    Zhou, Caicun
    Li, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] A bivalent Tim-3/PD-1 bispecific antibody for the treatment of PD-1 antibody resistant or refractory NSCLC.
    Liu, Jiajian
    Luan, Y.
    Deng, H.
    Wang, F.
    Wang, C.
    Zhang, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.
    Hellmann, Matthew David
    Shimizu, Toshio
    Doi, Toshihiko
    Hodi, F. Stephen
    Rottey, Sylvie
    Aftimos, Philippe Georges
    Liu, Zhuqing Tina
    de Mendizabal, Nieves Velez
    Szpurka, Anna M.
    Piao, Yongzhe
    Vangerow, Burkhard
    Gandhi, Leena
    Leow, Ching Ching
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
    Hellmann, Matthew D.
    Bivi, Nicoletta
    Calderon, Boris
    Shimizu, Toshio
    Delafontaine, Brant
    Liu, Zhuqing Tina
    Szpurka, Anna M.
    Copeland, Victoria
    Hodi, F. Stephen
    Rottey, Sylvie
    Aftimos, Philippe
    Piao, Yongzhe
    Gandhi, Leena
    Galvao, Violeta Regnier
    Leow, Ching Ching
    Doi, Toshihiko
    CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2773 - 2781
  • [5] GENERATION OF AZD7789, A NOVEL PD-1 AND TIM-3 TARGETING BISPECIFIC ANTIBODY, WHICH BINDS TO A DIFFERENTIATED EPITOPE OF TIM-3
    Clancy-Thompson, Eleanor
    Perry, Trinity
    Pryts, Stacy
    Jaiswal, Ashvin
    Oganesyan, Vaheh
    van Dyk, Nydia
    Yang, Chunning
    Garcia, Andrew
    Yu, Wenhan
    Moynihan, James
    Miller, Caroline
    Mulgrew, Kathy
    Cobbold, Mark
    Mazor, Yariv
    Hammond, Scott
    Pollizzi, Kristen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A481 - A481
  • [6] A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors
    Markman, Ben
    Tran, Ben
    Gan, Hui
    Prawira, Amy
    Coward, Jermaine
    Jin, Xiaoping
    Li, Baiyong
    Wang, Max
    Xia, Yu
    Desai, Jayesh
    Millward, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [7] Evaluation of the expression and function of TIM-3 relative to PD-1 in human tumors
    McEachern, Kristen
    Ghosh, Srimoyee
    Zhao, Yonghong
    Zhang, Qiyao
    Zhang, Norman
    Jenkins, David W.
    CANCER RESEARCH, 2017, 77
  • [8] Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumors
    Morgado, Micaela
    Datar, Ila
    Wang, Jun
    Sanmamed, Miguel F.
    McEachern, Kristen
    Jenkins, David
    Chen, Lieping
    Carvajal-Hausdorf, Daniel
    Rimm, David L.
    Herbst, Roy S.
    Schalper, Kurt A.
    CANCER RESEARCH, 2018, 78 (13)
  • [9] PHASE I STUDY OF ANTI PD-1 ANTIBODY ONO-4538 IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Nokihara, H.
    Yamada, Y.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Wakui, H.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 26 - 26
  • [10] Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors
    Qin, Shukui
    Cheng, Ying
    Wang, Qiming
    Cheng, Shuxia
    Chai, Xiaoli
    Wu, Lihua
    Yu, Yan
    Shi, Jianhua
    Li, Xiumin
    Fan, Lianlian
    Xia, Jin
    Huang, Yisheng
    Ji, Yinghua
    Zhuang, Zhixiang
    Yang, Lei
    Jiang, Ou
    Zheng, Qinhong
    Liao, Sihai
    Yi, Shanyong
    Ye, Huangyang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345